

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Company 2022/01/24 22:00:01

Price
621.48
 USD

Difference  0.01%(0.08)

REGENERON



Contact Details

REGENERON PHARMACEUTICALS INC.
 - -
 777 Old Saw Mill River Road
 10591-6707 Tarrytown

Tel: 1-914-847-7000
 Fax: -
 Web: <http://www.regeneron.com>
 E-mail: -

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as Velocimmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	9,779,100,000		7,689,100,000		6,447,600,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	7,384,200,000		7,116,100,000		5,286,900,000	
Equity capital of a company		11,025,300,000		11,089,700,000		8,757,300,000
Cash and cash equivalents	2,193,700,000		1,617,800,000		1,467,700,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,697,400,000		2,096,600,000		1,442,800,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,440,600,000		1,618,900,000		1,534,400,000
Different income		-		-		-
Other liabilities		744,900,000		905,000,000		825,900,000
Total assets	17,163,300,000	17,163,300,000	14,805,200,000	14,805,200,000	11,734,500,000	11,734,500,000

Balance notes

Accounting standard	2020	2019	2018
	US-GAAP	US-GAAP	US-GAAP
Employees	9,123	8,100	7,400
Equity ratio	64.24%	74.90%	74.63%
Debt-equity ratio	55.67%	33.50%	34.00%

Others

	2020	2019	2018
Tax Expense Rate	7.80%	12.90%	4.27%

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	8,497,100,000	7,863,400,000	6,710,800,000
Net income	3,513,200,000	2,115,800,000	2,444,400,000
EBIT	3,418,693,200	2,174,021,200	2,282,222,800
Operating income before taxes	3,810,400,000	2,429,100,000	2,553,500,000
Cash Flow	2,618,100,000	2,430,000,000	2,195,100,000
Net interest income	-56,900,000	-30,200,000	-28,200,000
Research and development expenses	2,499,100,000	2,826,300,000	2,037,900,000
Income taxes	297,200,000	313,300,000	109,100,000
Result from investments in subsidiaries, associates and other	-	-	0
Revenues per employee	823,352	858,178	801,669

Board of Directors

Members of Management Board

P. Vagelos	Chairman of Board of Directors
Bonnie Bassler	Member of Board of Directors
George Yancopoulos	Member of Board of Directors
Huda Zoghbi	Member of Board of Directors
Joseph Goldstein	Member of Board of Directors
Marc Tessier-Lavigne	Member of Board of Directors
Michael Brown	Member of Board of Directors
N. Coles	Member of Board of Directors
Arthur Ryan	Member of Board of Directors
Christine Poon	Member of Board of Directors
George Sing	Member of Board of Directors
Leonard S. Schleifer	Chairman of Managing Board
George D. Yancopoulos	Member of Executive Committee
Robert E. Landry	Member of Executive Committee